Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on oral drug delivery technology, has announced its participation in A.G.P.'s Annual Healthcare Company Showcase. The virtual presentation is scheduled for Wednesday, May 21, 2025, at 4:00 pm ET. Investors can access the presentation and its replay through the company's website's Investors section. The company's presentation will highlight its proprietary technology platform designed to enhance therapeutics through effective oral delivery solutions.
Positive
- None.
Negative
- None.
Presentation Details
Time: | 4:00 pm ET |
Date: | Wednesday, May 21, 2025 |
Webcast Link: | https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw |
The webcast and replay of the presentation will be accessible in the Investors section of Lipocine's website.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-agps-annual-healthcare-company-showcase-302454609.html
SOURCE Lipocine Inc.
FAQ
When is Lipocine (LPCN) presenting at A.G.P.'s Healthcare Company Showcase 2025?
How can investors access Lipocine's presentation at the A.G.P. Healthcare Showcase?
What is Lipocine's (LPCN) main business focus?
Is the A.G.P. Healthcare Company Showcase 2025 an in-person or virtual event?
